awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27
Q33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27
New dosing schedules of dasatinib for CML and adverse event management
P2860
Q33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33383407-58E6AE5B-AB3C-40A5-8A1E-207C99A19F27
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b9cd471f9c03c29bac07b2b630bc8ddd5d336431
P2860
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.